MedTrace Logo

Essential Amino Acid Supplementation Enhances Post-prandial Amino Acid Availability Following a Standard-protein Breakfast in Older Adults

NCT07754760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-08-10

No results posted yet for this study

Summary

Healthy older adults and those who have acute and chronic conditions suffer from reduced protein intake and are at risk of developing both chronic and acute sarcopenia. Amino acid supplementation can provide appropriate conditions for muscle protein synthesis to occur. However, the exact amino acid ratio that may optimise this is currently unknown. The purpose of this crossover trial is to compare different amino acid gels and identify which results in the greatest concentration of plasma amino acids following a standardised breakfast. This will allow development of management strategies for healthy and diseased populations who suffer from reduced protein intake.

Conditions

  • Older Adults Without Any Specific Clinical Condition

Interventions

DIETARY_SUPPLEMENT

Essential amino acid supplement

Two active comparators containing a unique composition of essential amino acids reported previously by Ispoglou et al. (2016; 2017) and Kobayashi et al. (2010).

DIETARY_SUPPLEMENT

Placebo

An energy-matched plaecbo supplement containing no amino acids.

Sponsors & Collaborators

  • Leeds Beckett University

    lead OTHER

Principal Investigators

  • Theocharis Ispoglou, PhD · Leeds Beckett University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-17
Primary Completion
2022-12-09
Completion
2022-12-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07754760 on ClinicalTrials.gov